Alyeska Investment Group
AMBI

Alyeska Investment Group’s Ambit Biosciences Corp AMBI Stock Holding History

Alyeska Investment Group’s Portfolio AMBI Stock Details AMBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-74,989
Closed -$525K – 397
2013
Q2 		$525K Buy
+74,989
New +$536K 0.03% 256

Other funds holding AMBI

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group's AMBI Position: Q3 2013 in Review

Alyeska Investment Group sold out of Ambit Biosciences Corp (AMBI) in Q3 2013, closing a stake of 74,989 shares — an estimated $525K sold.

Alyeska Investment Group first reported a position in AMBI in Q2 2013 and held it in 1 quarter. The position peaked at $525K in Q2 2013. 23 funds tracked by Wall St. Rank hold AMBI as of Q3 2013.

  • Alyeska Investment Group reported no remaining Ambit Biosciences Corp position as of Q3 2013 after selling out during the quarter.
  • Alyeska Investment Group sold 74,989 Ambit Biosciences Corp shares in Q3 2013, an estimated $525K.
  • Alyeska Investment Group first reported a position in Ambit Biosciences Corp in Q2 2013 and held it in 1 quarter.
  • Alyeska Investment Group's Ambit Biosciences Corp position peaked at $525K in Q2 2013.
  • 23 funds tracked by Wall St. Rank held Ambit Biosciences Corp as of Q3 2013.

Based on Alyeska Investment Group's 13F filing for Q3 2013, filed 14 Nov 2013.